Cargando…

MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM

Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Murgić, Jure, Gregov, Marin, Mrčela, Iva, Budanec, Mirjana, Krengli, Marco, Fröbe, Ana, Franco, Pierfrancesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022406/
https://www.ncbi.nlm.nih.gov/pubmed/36938552
http://dx.doi.org/10.20471/acc.2022.61.s3.9
_version_ 1784908724559675392
author Murgić, Jure
Gregov, Marin
Mrčela, Iva
Budanec, Mirjana
Krengli, Marco
Fröbe, Ana
Franco, Pierfrancesco
author_facet Murgić, Jure
Gregov, Marin
Mrčela, Iva
Budanec, Mirjana
Krengli, Marco
Fröbe, Ana
Franco, Pierfrancesco
author_sort Murgić, Jure
collection PubMed
description Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice.
format Online
Article
Text
id pubmed-10022406
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
record_format MEDLINE/PubMed
spelling pubmed-100224062023-03-18 MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM Murgić, Jure Gregov, Marin Mrčela, Iva Budanec, Mirjana Krengli, Marco Fröbe, Ana Franco, Pierfrancesco Acta Clin Croat Professional Papers Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice. Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2022-10 /pmc/articles/PMC10022406/ /pubmed/36938552 http://dx.doi.org/10.20471/acc.2022.61.s3.9 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Professional Papers
Murgić, Jure
Gregov, Marin
Mrčela, Iva
Budanec, Mirjana
Krengli, Marco
Fröbe, Ana
Franco, Pierfrancesco
MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title_full MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title_fullStr MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title_full_unstemmed MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title_short MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
title_sort mri-guided radiotherapy for prostate cancer: a new paradigm
topic Professional Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022406/
https://www.ncbi.nlm.nih.gov/pubmed/36938552
http://dx.doi.org/10.20471/acc.2022.61.s3.9
work_keys_str_mv AT murgicjure mriguidedradiotherapyforprostatecanceranewparadigm
AT gregovmarin mriguidedradiotherapyforprostatecanceranewparadigm
AT mrcelaiva mriguidedradiotherapyforprostatecanceranewparadigm
AT budanecmirjana mriguidedradiotherapyforprostatecanceranewparadigm
AT krenglimarco mriguidedradiotherapyforprostatecanceranewparadigm
AT frobeana mriguidedradiotherapyforprostatecanceranewparadigm
AT francopierfrancesco mriguidedradiotherapyforprostatecanceranewparadigm